Print Page  Close Window    

Investor Relations Home

Corporate Profile

La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.

Featured Documents

12/22/17GIAPREZA™ (angiotensin II) Update

Share Price

Stock chart for: LJPC.OQ.  Currently trading at $32.15 with a 52 week high of $41.24 and a 52 week low of $16.78.
Price$32.15
Change (%) Stock is Down 0.46 (1.41%)
Volume235,462
Data as of 02/23/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.


Upcoming Events




There are currently no events scheduled.

Recent News


La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress

02/22/18

SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases,

Read More

La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA™ (angiotensin II) Pediatric Study

02/21/18

SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that the first pediatric patient has been treated in LJ501-CRH02, La Jolla’s open-label study of GIAPREZATM (angiotensin II), injection for i

Read More

La Jolla Pharmaceutical Company Announces FDA Approval of Giapreza™ (angiotensin II)

12/21/17

Giapreza increases blood pressure in adults with septic or other distributive shock La Jolla to host conference call and webcast at 8:30 a.m. EST on December 22, 2017 SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (N

Read More